title: A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge.
abstract: BACKGROUND
  Zafirlukast, a leukotriene antagonist, has been shown to have protective effects against a variety of asthma triggers.
  
  
  OBJECTIVE
  Our purpose was to evaluate zafirlukast's effects on upper and lower airway responses to cat allergen exposure with use of a well-characterized cat exposure model.
  
  
  METHODS
  In a double-blind, placebo-controlled, cross-over trial 18 subjects with cat-induced asthma were randomly assigned to receive 1 week each of zafirlukast or placebo followed by a 1-hour cat challenge. Upper and lower respiratory symptoms were rated and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject was too uncomfortable or had a >50% decrease in FEV(1).
  
  
  RESULTS
  Overall changes in FEV(1) were significantly different with zafirlukast treatment (P = .02). Significant differences in FEV(1) change were detected at 15 and 30 minutes (P = .027 and .05, respectively) but not at 45 and 60 minutes. Changes in acoustic rhinometry were also significantly different at 15 and 30 minutes (P =.05 and .0005, respectively) but not at 45 and 60 minutes. Challenge length was significantly longer with zafirlukast versus placebo after adjustment for differences in allergen exposure (P = .022). Respiratory symptom scores were significantly different (lower respiratory, P < .001; upper respiratory, P = .038) through the first 30 minutes of the challenge after adjustment for allergen exposure.
  
  
  CONCLUSIONS
  Zafirlukast was significantly more effective than placebo in preserving pulmonary function and nasal anatomy and extending challenge length when cat-sensitive asthmatic subjects were exposed to high levels of cat allergen.
authors.affiliation: Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors.forename: W
authors.initials: W
authors.lastname: Phipatanakul
authors.forename: P A
authors.initials: PA
authors.lastname: Eggleston
authors.forename: M K
authors.initials: MK
authors.lastname: Conover-Walker
authors.forename: J
authors.initials: J
authors.lastname: Kesavanathan
authors.forename: D
authors.initials: D
authors.lastname: Sweitzer
authors.forename: R A
authors.initials: RA
authors.lastname: Wood
mesh_terms: D000328:Adult; D000485:Allergens / Q000009:adverse effects / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D002415:Cats / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006023:Glycoproteins; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates; D012130:Respiratory Hypersensitivity / Q000276:immunology*; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use*
chemical_list: D000485:Allergens; D006023:Glycoproteins; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; C059296:Fel d 1 protein, Felis domesticus; C062735:zafirlukast